dry.eye-portal.ru

Ткаченко Наталья Викторовна, Астахов Юрий Сергеевич (ПСПбГМУ им. акад. И.П. Павлова Минздрава России, Санкт-Петербург).

Частота выявления синдрома «сухого глаза» среди пациентов развитых стран ежегодно растет. Это служит источником постоянного научного поиска эффективных и безопасных методов его лечения, новых офтальмологических препаратов.

В связи с регистрацией в РФ Хилопарин®-Комод, Hyloparin-Comod" (Урсафарм), содержащего в своем составе гепарин, на базе нашей кафедры было проведено исследование эффективности препарата в лечении различной офтальмопатологии, протекающей на фоне ССГ.

The experience of “hyloparin” use in clinical practice

Tkachenko N. V., Astakhov S. Yu.

Summary.
The incidence of the “dry eye” syndrome diagnosis in developed countries increases from year to year. It is a reason for continuous scientific search for effective and safe methods for its treatment, for new ophthalmic medications.

Because of the registration in the Russian Federation of “Hyloparin-Comod” containing heparin, our chair carried out a study on the efficacy of the medication in treatment of several eye diseases associated with the “dry eye” syndrome.

Список литературы:

1. Бржеский В.В., Астахов Ю.С., Кузнецова Н.Ю. Заболевания слезного аппарата. СПб.: Изд-во Н-Л, 2009. (Brzheskiy V. V., Astakhov Yu. S., Kuznetsova N. Yu. Zabolevaniya sleznogo apparata [Diseases of the lacrimal apparatus]. SPb.: Izd-vo N-L, 2009.)

2. Егорова Г.Б., Митичкина Т.С., Шамсудинова А.Р. Оценка возможностей коррекции синдрома «сухого глаза» при ношении контактных линз. Клинич. офтальмол, 2014; 4: 198-203. (Egorova G. B., Mitichkina T. S., Shamsudinova A. R. Otsenka vozmozhnostey korrektsii sindroma “sukhogo glaza” pri noshenii kontaktnykh linz [Assessment opportunities correction syndrome dry eye while wearing contact lenses]. Klinich. oftal'mol, 2014; 4: 198–203.)

3. Кудряшова Ю.И. Современные подходы к терапии иммуноопосредованной формы синдрома «сухого глаза». Клинич. офтальмол., 2010; 1: 16–20. (Kudryashova Yu. I. Sovremennye podkhody k terapii immunoo-posredovannoy formy sindroma “sukhogo glaza” [Modern ap- proaches to therapy immunopositive forms of dry eye syndrome]. Klinich. oftal'mol, 2010; 1: 16–20.)

4. Милюдин Е.С., Золотарев А.В., Милюдин А.Е. Возможности местной иммуносупрессии при повторной кератопластике. Клинич. офтальмол., 2014; 3: 160-63. (Milyudin E. S., Zolotarev A. V., Milyudin A. E. Vozmozhnosti mestnoy immunosupressii pri povtornoy keratoplastike [Opportuni-ties for local immunosuppression when re-keratoplasty]. Klinich. oftal'mol., 2014; 3: 160-63.)

5. Смердова А. В. Характеристика протекторного действия гепарина при введении этанола и пчелиного яда экспериментальным животным. Автореф. дис... канд. биол. наук. Нижний Новгород, 2011. (Smerdova A. V. Kharakteristika protektornogo deystviya geparina pri vvedenii etanola i pchelinogo yada eksperimental'nym zhivotnym [Characterization of the protective action of heparin in the introduction of ethanol and bee venom experimental animals]. Av- toref. dis... kand. biol. nauk. Nizhniy Novgorod, 2011.)

6. Altinbas M., Dikilitas M., Ozkan M., Dogu G. G., Er O., Coskun H. S. The effect of small-molecular-weight heparin added to chemotherapy on survival in small-cell lung cancer — A retrospective analysis. Indian J Cancer, 2014; 51 (3): 324–29.

7. Aydin E., Kivilcim M., Peyman G. A., Esfahani M. R., Kazi A. A., Sanders D. R. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline. Cornea, 2008; 27 (4): 446–53.

8. Basti S., Aasuri M. K., Reddy M. K., Preetam P., Reddy S., Gupta S., Naduvilath T. J. Heparin-surface-modified intraocular lenses in pediatric cataract surgery: prospective randomized study. J Cataract Refract Surg, 1999; 25 (6): 782–87.

9. Baudouin C., Pisella P. J., Fillacie K. et al. Ocular Surface Inflammatory changes induced by topical antiglaucoma drugs.Ophthalmology, 1999; 106: 556–63.

10. Bozac E., Brief G., Margesco F., Munteanu H. Heparin in the treatment of ocular burns caused by bases. Ann Ocul (Paris), 1967; 200 (6): 693–700.

11. Byun Y.S., Rho C.R., Cho K., Choi J.A., Na K.S., Joo C.K. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study. Korean J Ophthalmol. 2011; 25 (6): 369–74.

12. Charteris D. G., Aylward G. W., Wong D., Groenewald C., Asa- ria R. H., Bunce C. PVR study group. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology, 2004; 111: 2240–245.

13. Dastjerdi M. H., Hamrah P., Dana R. High-frequency topical cyclosporine 0.05 % in the treatment of severe dry eye refractory to twice-daily regimen. Cornea, 2009; 28 (10): 1091–96.

14. De Paiva C. S., Corrales R. M., Villarreal A. L., Farley W. J., Li D. Q., Stern M. E. et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res, 2006; 83: 526–535.

15. Debbasch C., Brignole F., Pisella P.-J., BaudouinC. et al. Quaternary Ammoniums and Other Preservatives’ Contribution in Oxidative Stress and Apoptosis on Chang Conjunctival Cells.Inves- tigative Ophthalmology and Visual Science, 2001; 42: 642–52.

16. Denk P. O., Knorr M. Effect of heparin on human corneal fibroblast proliferation in vitro with and without growth factor stimulation. Graefes Arch Clin Exp Ophthalmol, 1999; 237 (4): 342–47.

17. Devecı H., Kobak S. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome. Int Ophthalmol. 2014; 34 (5): 1043–48.

18. Ellison A., Poirier R. Therapeutic effects of heparin on Pseudomo- nasinduced corneal ulceration. Am J Ophthalmol, 1976; 82 (4): 619–27.

19. Fredj-Reygrobellet D., Hristova D. L., Ettaiche M., Meddahi A., Jozefonwicz J., Barritault D. CMDBS, functional analogue of heparin sulfate as a new class of corneal ulcer healing agents. Ophthalmic Res, 1994; 26 (6): 325–31.

20. Ganekal S., Dorairaj S. Effect of intraoperative 5-fluorouracil and low molecular weight heparin on the outcome of high-risk proliferative vitreoretinopathy Saudi J Ophthalmol, 2014; 28 (4): 257–61.

21. Gayton J. L. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009; 3: 405–12.

22. Hessen M., Akpek E. K. Dry Eye: an Inflammatory Ocular Disease J Ophthalmic Vis Res, 2014; 9 (2): 240–50.

23. Hiremath M., Elder J., Newall F., Mitchell S., Dyas R., Monagle P. Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature. Blood Coagul Fibrinolysis, 2011; 22 (7): 606–9.

24. Hoppenreijs V. P., Pels E., Felten P. C., Ruijter J. M., Vrensen G. F., Treffers W. F. Synergistic action of heparin and serum on basic fibroblast growth factor-modulated DNA synthesis and mitochondrial activity of cultured bovine corneal endothelial cells. Cornea,
1996; 15 (4): 386–96.

25. Kim J., Al-Hilal T. A., Chung S. W., Kim S. Y., Ryu G. H., Son W. C., Byun Y. Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention. J Control Release, 2014 Dec 15. pii: S0168–3659 (14)00812–8. doi: 10.1016/j.jconrel.2014.12.015. [Epub ahead of print].

26. Knorr M., Wunderlich K., Steuhl K. P., Thiel H. J. Effect of heparin and ascorbic acid on growth behavior of cultivated corneal epithelial cells of the rabbit. Ophthalmologe, 1996; 93 (3): 275–78.

27. Kocatürk T., Kocatürk O., Kaplan A., Meteoğlu I., Cakmak H., Dayanir V. Heparin treatment for allergic conjunctivitis in the experimental BALB/c model. Ophthalmic Res, 2013; 50 (1): 65–71.

28. Ku J. Y., Lichtinger A., Yeung S. N., Kim P., Cserti-Gazdewich C., Slomovic A. R. Topical fresh frozen plasma and heparin treatment of ligneous conjunctivitis in a Canadian hospital setting. Can J Ophthalmol, 2012; 47 (5): 27–8.

29. Kymionis G. D., Bouzoukis D. I., Diakonis V. F., Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol, 2008; 2 (4): 829–36.

30. Leung E. W., Medeiros F. A., Weinreb R. N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma, 2008; 17 (5): 350–355.

31. Marsh P., Pflugfelder S. C. Topical nonpreserved methylpresdnisolone therapy of keratoconjunctivits sicca in sjogren’s syn- drome. Ophthalmology, 1999; 106: 811–816.

32. McGhee C. N., Dean S., Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf, 2002; 25: 33–55.

33. Michels R., Michels S., Kaminski S. Effect of combined topical heparin and steroid on corneal neovascularization in children. Ophthalmic Surg Lasers Imaging, 2012; 43 (6): 452–58.

34. Nikolic L., Friend J., Taylor S., Thoft R. A. Inhibition of vascularization in rabbit corneas by heparin: cortisone pellets. Invest Ophthalmol Vis Sci, 1986; 27 (4): 449–56.

35. Ning F., Wang X., Shang L., Wang T., Lv C., Qi Z., Wu D. Low molecular weight heparin may prevent acute lung injury induced by sepsis in rats. Gene, 2014 Dec 10. pii: S0378–1119 (14)01414–0. doi: 10.1016/j.gene.2014.12.018. [Epub ahead of print].

36. Niu G., Choi J. S., Wang Z., Skardal A., Giegengack M., Soker S. Heparin-modified gelatin scaffolds for human corneal endothelial cell transplantation. Biomaterials, 2014; 35 (13): 4005– 14.

37. Peyman G. A., Kazi A. A., Riazi-Esfahani M., Aydin E., Kivilcim M., Sanders D. R. The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. Cornea, 2006; 25 (5): 582–5.

38. Pflugfelder S. C., Maskin S. L., Anderson B., Chodosh J., Holland E. J., De Paiva C. S., et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clear- ance. Am J Ophthalmol, 2004; 138: 444–57.

39. Prabhasawat P., Tesavibul N., Karnchanachetanee C., Kasemson S. Efficacy of cyclosporine 0.05 % eye drops in Stevens Johnson syndrome with chronic dry eye. J Ocul Pharmacol Ther, 2013; 29 (3): 372–77.

40. Princz M. A., Sheardown H. Heparin-modified dendrimer crosslinked collagen matrices for the delivery of heparin-binding epidermal growth factor. J Biomed Mater Res A, 2012; 100 (8): 1929–37.

41. Rieck P., Denis J., Peters D., Hartmann C., Pouliquen Y., Courtois Y. Fibroblast growth factor 2, heparin and suramin reduce epithelial ulcer development in experimental HSV-1 keratitis. Graefes Arch Clin Exp Ophthalmol, 1997; 235 (11): 733–40.

42. SchultzС. Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye. Ophthalmol Eye Dis, 2014; 6: 37–42.

43. Shah S. M., Spalton D. J. Comparison of the postoperative inflammatory response in the normal eye with heparin-surface-modified and poly (methyl methacrylate) intraocular lenses. J Cataract Refract Surg, 1995; 21 (5): 579–85.

44. Smith J. A., Albeitz J. et al. Epidemiology DEWS Subcommittee. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf, 2007; 5 (2): 93–107.

45. Solomon A., Dursun D., Liu Z., Xie Y., Macri A., Pflugfelder S. C. Proand anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthal- 2. mol Vis Sci, 2001; 42: 2283–92.

46. Stern M. E., Gao J., Schwalb T. A., Ngo M,. Tieu D.D, Chan C. C., et al. Conjunctival T-cell subpopulations in Sjögren’s and non-Sjögren’s patients with dry eye. Invest Ophthalmol Vis Sci, 2002; 43: 2609–14.

47. Tan H., Yang S., Liu C., Cao J., Mu G., Wang F. Enhanced antiangiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin. Biomed Pharmacother, 2012; 66 (8): 648–54.

48. Uesugui E, Dantas PE, Nishiwaki-Dantas MC, Mimica LJ. Antibacterial activity of anesthetic solutions and preservatives: an in vitro comparative study.Cornea, 2000; 19 (3): 353–54.

49. Venkatachalapathy T. S. A comparative study of paediatric ther- 5. mal burns treated with topical heparin and without heparin. Indian J Surg, 2014; 76 (4): 282–7.

50. Wilson M. E. Jr, Trivedi R. H. Low molecular-weight heparin in the intraocular irrigating solution in pediatric cataract and intraocular lens surgery. Am J Ophthalmol, 2006; 141 (3): 537–38.

51. Yoon S. Y., Kim J. Y., Kim E. S., Kim S. Y., Kim M. J., Tchah H. Subconjunctival injection of low-molecular-weight heparin-tauro-cholate 7 inhibits corneal neovascularization. Cornea, 2013; 32 (11): 1488–92.

52. Zarei R., Azimi R., Moghimi S., Abdollahi A., Amini H., Eslami Y., Fakhraii G. Inhibition of intraocular fibrin formation after infusion of low-molecular-weight heparin during combined phacoemulsi-fication-trabeculectomy surgery. J Cataract Refract Surg, 2006; 32 (11): 1921–25.

53. Zhou X. Q., Wei R. L. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis. Cornea, 2014; 33 (7): 760–67.

Опубликовано: ОФТАЛЬМОЛОГИЧЕСКИЕ ВЕДОМОСТИ, Том VII, No 4, 2014, стр. 53-62.

Примечание:

Материал для публикации на портале Орган зрения organum-visus.com любезно предоставила компания URSAPHARM.

Внимание! Данная информация предназначена исключительно для ознакомления.

Любое применение опубликованного материала возможно только после консультации со специалистом.




Разрешается некоммерческое цитирование материалов данного раздела при условии полного указания источника заимствования: имени автора и WEB-адреcа данного раздела www.dry.eye-portal.ru, www.organum-visus.com